RESUMEN
ETHNOPHAMACOLOGICAL RELEVANCE: Morinda officinalis oligosaccharides (MOs) is a mixture of oligosaccharides extracted from the roots of Morinda officinalis (MO). It is approved by Chinese Food and Drug Administration (CFDA) for depression treatment. MOs could improve the antidepressant efficacy of escitalopram in clinic. AIM OF THE STUDY: We aim to explore the antidepressant activity and potential mechanism of the combination usage of MOs and escitalopram on animal model of depression. MATERIALS AND METHODS: Depressive animal model was induced by chronic mild stress (CMS). Behavioral tests were conducted to evaluate the antidepressant efficacy of MOs and escitalopram. Serum neurotransmitter levels were detected by High-performance liquid chromatography (HPLC). Quantitative real-time PCR and Western blotting were applied to assay the hippocampus neurotrophic factors' mRNA and protein levels. Peripheral cytokines levels were measured through Enzyme-Linked Immunosorbent Assay (ELISA). Micorglia polization phenotype was assayed by immunofluorescence and flow cytometry. RESULTS: MOs and escitalopram obviously attenuated depression-like behaviors of CMS mice. Importantly, MOs plus escitalopram exhibited better antidepressant activity on CMS mice than monotherapy. At the same time, MOs combined escitalopram treatment significantly increased hippocampus neurotransmitters and neurotrophic factor levels, stimulated hippocampus neurogenesis and relieved central nervous system (CNS) microglia over-activation of CMS mice. The combination therapy had greater effect on neuroprotection and inflammation attenuation of CMS mice than monotherapy. CONCLUSION: Our results indicates MOs combined escitalopram might produce antidepressant activity through protecting neuron activity, relieving inflammation and modulating microglia polarization process.
Asunto(s)
Escitalopram , Morinda , Ratones , Animales , Depresión/tratamiento farmacológico , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Inflamación/tratamiento farmacológico , Estrés Psicológico/tratamiento farmacológico , Modelos Animales de EnfermedadRESUMEN
Human milk is the most valuable source of nutrition for infants. The structure and function of human milk oligosaccharides (HMOs), which are key components of human milk, have long been attracting particular research interest. Several recent studies have found HMOs to be efficacious in the prevention and treatment of necrotizing enterocolitis (NEC). Additionally, they could be developed in the future as non-invasive predictive markers for NEC. Based on previous findings and the well-defined functions of HMOs, we summarize potential protective mechanisms of HMOs against neonatal NEC, which include: modulating signal receptor function, promoting intestinal epithelial cell proliferation, reducing apoptosis, restoring intestinal blood perfusion, regulating microbial prosperity, and alleviating intestinal inflammation. HMOs supplementation has been demonstrated to be protective against NEC in both animal studies and clinical observations. This calls for mass production and use of HMOs in infant formula, necessitating more research into the safety of industrially produced HMOs and the appropriate dosage in infant formula.
Asunto(s)
Enterocolitis Necrotizante , Leche Humana , Lactante , Animales , Recién Nacido , Humanos , Leche Humana/química , Enterocolitis Necrotizante/tratamiento farmacológico , Enterocolitis Necrotizante/prevención & control , Intestinos , Proliferación Celular , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Oligosacáridos/análisisRESUMEN
Xiasangju (XSJ) is a traditional Chinese herbal formula consisted of Prunella spica, Mulberry leaf and Chrysanthemi indici flos, which can be used to treat fever, headache and ulcer. To explore the effects of oligosaccharides from XSJ (OX) on colitis, we used dextran sulfate sodium (DSS) to establish colitis mouse models. After administration of OX with different doses on the control and colitis mice, we measured their body weights, disease activity indexes (DAI), lengths and histopathologic changes of colons, spleen indexes. The inflammatory cytokines and oxidative stress-related factors in serum, and the intestinal microbial community in feces were also detected. We found that colitis mice with oral administration of OX showed higher body weights and lower levels of DAI and spleen index. Tissue damages induced by DSS were also alleviated by OX treatment. The colitis mice with OX treatment exhibited lower levels of AST, ALT, BUN, CR, MDA and a down-regulated expression of IL-6 and IL-1ß, while the activity of SOD was up-regulated. Furthermore, OX improved the relative abundance of gut microbiota and restored the proportions of Bacteroidetes and Muribaculaceae. We found that oligosaccharides from XSJ alleviated the symptoms of colitis mice through its inhibitory effects on inflammation and oxidative stress, and also regulated the composition of intestinal flora, which indicates a beneficial role for patients with colitis.
Asunto(s)
Colitis Ulcerosa , Colitis , Humanos , Animales , Ratones , Sulfato de Dextran/toxicidad , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Colitis/metabolismo , Inflamación/patología , Colon/patología , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Oligosacáridos/metabolismo , Peso Corporal , Ratones Endogámicos C57BL , Modelos Animales de Enfermedad , Colitis Ulcerosa/tratamiento farmacológicoRESUMEN
Polygalae radix (PR) is a well-known traditional Chinese medicine that is used to treat depression, and polygalae radix oligosaccharide esters (PROEs) are the main active ingredient. Although gut microbiota are now believed to play key role in depression, the effects of PROEs on depression via modulation of gut microbiota remain unknown. In this article, we investigate the effect of PROEs on the gut microbiota of a depression rat and the possible mechanism responsible. The depression rat model was induced by solitary rearing combined with chronic unpredictable mild stress (CUMS). The depression-like behavior, the influence on the hypothalamic-pituitary-adrenal (HPA) axis, the contents of monoamine neurotransmitter in the hippocampus, and the quantity of short-chain fatty acids (SCFAs) in the feces were each assessed, and the serum levels of lipopolysaccharide (LPS) and interleukin-6 (IL-6) were measured by ELISA. Additionally, ultrastructural changes of the duodenal and colonic epithelium were observed under transmission electron microscope, and the gut microbiota were profiled by using 16S rRNA sequencing. The results show that PROEs alleviated the depression-like behavior of the depression model rats, increased the level of monoamine neurotransmitters in the brain, and reduced the hyperfunction of the HPA axis. Furthermore, PROEs regulated the imbalance of the gut microbiota in the rats, relieving intestinal mucosal damage by increasing the relative abundance of gut microbiota with intestinal barrier protective functions, and adjusting the level of SCFAs in the feces, as well as the serum levels of LPS and IL-6. Thus, we find that PROEs had an antidepressant effect through the restructuring of gut microbiota that restored the function of the intestinal barrier, reduced the release of intestinal endotoxin, and constrained the inflammatory response.
Asunto(s)
Depresión , Microbioma Gastrointestinal , Ratas , Animales , Depresión/tratamiento farmacológico , Depresión/etiología , Sistema Hipotálamo-Hipofisario , Interleucina-6/farmacología , ARN Ribosómico 16S , Lipopolisacáridos/farmacología , Sistema Hipófiso-Suprarrenal , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Estrés Psicológico/tratamiento farmacológicoRESUMEN
Postmenopausal osteoporosis is the most common type of osteoporosis. Chondroitin sulfate (CS) has been successfully employed as food supplement against osteoarthritis, while the therapeutic potential on postmenopausal osteoporosis is little explored. In this study, CS oligosaccharides (CSOs) were enzymatically prepared through the lysis of CS by a chondroitinase from Microbacterium sp. Strain. The alleviating effects of CS, CSOs and Caltrate D (a clinically used supplement) on ovariectomy (OVX) - induced rat's osteoporosis were comparatively investigated. Our data showed that the prepared CSOs was basically unsaturated CS disaccharide mixture of ∆Di4S (53.1%), ∆Di6S (27.7%) and ∆Di0S (17.7%). 12 weeks' intragastric administration of Caltrate D (250 mg/kg/d), CS or CSOs (500 mg/kg/d, 250 mg/kg/d, 125 mg/kg/d) could obviously regulate the disorder of serum indices, recover the mechanical strength and mineral content of bone, improve the cortical bones' density and the number and length of trabecular bones in OVX rats. Both CS and CSOs in 500 mg/kg/d and 250 mg/kg/d could restore more efficiently the serum indices, bone fracture deflection and femur Ca than Caltrate D. As compared with CS at the same dosage, CSOs exhibited a more significant alleviating effect. These findings suggested that there was great potential of CSOs as daily interventions for delaying the progression of postmenopausal osteoporosis.
Asunto(s)
Osteoporosis Posmenopáusica , Osteoporosis , Femenino , Humanos , Ratas , Animales , Sulfatos de Condroitina/uso terapéutico , Sulfatos de Condroitina/farmacología , Osteoporosis Posmenopáusica/tratamiento farmacológico , Osteoporosis/tratamiento farmacológico , Osteoporosis/etiología , Densidad Ósea , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , OvariectomíaRESUMEN
κ-Selenocarrageenan (KSC) is an organic selenium (Se) polysaccharide. There has been no report of an enzyme that can degrade κ-selenocarrageenan to κ-selenocarrageenan oligosaccharides (KSCOs). This study explored an enzyme, κ-selenocarrageenase (SeCar), from deep-sea bacteria and produced heterologously in Escherichia coli, which degraded KSC to KSCOs. Chemical and spectroscopic analyses demonstrated that purified KSCOs in hydrolysates were composed mainly of selenium-galactobiose. Organic selenium foods through dietary supplementation could help regulate inflammatory bowel diseases (IBD). This study discussed the effects of KSCOs on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in C57BL/6 mice. The results showed that KSCOs alleviated the symptoms of UC and suppressed colonic inflammation by reducing the activity of myeloperoxidase (MPO) and regulating the unbalanced secretion of inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-6 and IL-10). Furthermore, KSCOs treatment regulated the composition of gut microbiota, enriched the genera Bifidobacterium, Lachnospiraceae_NK4A136_group and Ruminococcus and inhibited Dubosiella, Turicibacter and Romboutsia. These findings proved that KSCOs obtained by enzymatic degradation could be utilized to prevent or treat UC.
Asunto(s)
Carragenina , Colitis Ulcerosa , Microbioma Gastrointestinal , Compuestos de Organoselenio , Animales , Ratones , Colitis Ulcerosa/prevención & control , Colitis Ulcerosa/terapia , Sulfato de Dextran , Modelos Animales de Enfermedad , Microbioma Gastrointestinal/efectos de los fármacos , Interleucina-6/metabolismo , Ratones Endogámicos C57BL , Oligosacáridos/química , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Factor de Necrosis Tumoral alfa/metabolismo , Carragenina/farmacología , Carragenina/uso terapéutico , Compuestos de Organoselenio/farmacología , Compuestos de Organoselenio/uso terapéuticoRESUMEN
Alginate oligosaccharides (AOS) are shown to have various biological activities of great value to medicine, food, and agriculture. However, little information is available about their beneficial effects and mechanisms on ulcerative colitis. In this study, AOS with a polymerization degree between 2 and 4 were found to possess anti-inflammatory effects in vitro and in vivo. AOS could decrease the levels of nitric oxide (NO), IL-1ß, IL-6, and TNFα, and upregulate the levels of IL-10 in both RAW 264.7 and bone-marrow-derived macrophage (BMDM) cells under lipopolysaccharide (LPS) stimulation. Additionally, oral AOS administration could significantly prevent bodyweight loss, colonic shortening, and rectal bleeding in dextran sodium sulfate (DSS)-induced colitis mice. AOS pretreatment could also reduce disease activity index scores and histopathologic scores and downregulate proinflammatory cytokine levels. Importantly, AOS administration could reverse DSS-induced AMPK deactivation and NF-κB activation in colonic tissues, as evidenced by enhanced AMPK phosphorylation and p65 phosphorylation inhibition. AOS could also upregulate AMPK phosphorylation and inhibit NF-κB activation in vitro. Moreover, 16S rRNA gene sequencing of gut microbiota indicated that supplemental doses of AOS could affect overall gut microbiota structure to a varying extent and specifically change the abundance of some bacteria. Medium-dose AOS could be superior to low- or high-dose AOS in maintaining remission in DSS-induced colitis mice. In conclusion, AOS can play a protective role in colitis through modulation of gut microbiota and the AMPK/NF-kB pathway.
Asunto(s)
Alginatos , Colitis Ulcerosa , Colitis , Microbioma Gastrointestinal , Proteínas Quinasas Activadas por AMP , Alginatos/uso terapéutico , Animales , Colitis/inducido químicamente , Colitis/tratamiento farmacológico , Colitis/metabolismo , Colitis Ulcerosa/tratamiento farmacológico , Sulfato de Dextran/efectos adversos , Modelos Animales de Enfermedad , Ratones , Ratones Endogámicos C57BL , FN-kappa B/metabolismo , Oligosacáridos/uso terapéutico , ARN Ribosómico 16SRESUMEN
Iron deficiency remains the most common nutritional deficiency. Oral iron supplementation is the recommended first-line treatment and used as a preventive measure as well. Enhancers of iron absorption are highly sought after to improve supplementation outcomes. Evidence from animal and human studies exists that prebiotics can enhance iron absorption. The purpose of this present narrative review of the literature is to summarize the existing evidence on the effects of prebiotics on human iron absorption. Relevant articles were identified from PUBMED, Scopus, and Web of Science from inception to November 2021. Only human trials investigating the effect of prebiotics on iron absorption were included. Eleven articles were identified and included for review. There are promising findings supporting an enhancing effect of certain prebiotics, but inconsistencies between the studies and results exist. The most convincing evidence exists for the prebiotics galacto-oligosaccharides and fructo-oligosaccharides combined with the commonly used iron compound ferrous fumarate, from studies in adult women with low iron stores and in anemic infants. Many factors seem to play a role in the enhancing effect of prebiotics on iron absorption such as type of prebiotic, dose, acute (single-dose) or chronic (long-term) prebiotic consumption, iron compound, iron status, inflammatory status, and age of the population studied. More research investigating the optimal combination of prebiotic, iron compound, and dose as well as the effect of long-term application on iron status outcomes is needed.
Asunto(s)
Anemia Ferropénica , Prebióticos , Lactante , Adulto , Animales , Humanos , Femenino , Hierro/farmacología , Hierro/uso terapéutico , Anemia Ferropénica/prevención & control , Anemia Ferropénica/tratamiento farmacológico , Oligosacáridos/farmacología , Oligosacáridos/uso terapéuticoRESUMEN
Infant allergy is the most common early manifestation of an increasing propensity for inflammation and immune dysregulation in modern environments. Refined low-fibre diets are a major risk for inflammatory diseases through adverse effects on the composition and function of gut microbiota. This has focused attention on the potential of prebiotic dietary fibres to favourably change gut microbiota, for local and systemic anti-inflammatory effects. In pregnancy, the immunomodulatory effects of prebiotics may also have benefits for the developing fetal immune system, and provide a potential dietary strategy to reduce the risk of allergic disease. Here, we present the study protocol for a double-blinded, randomised controlled trial investigating the effects of maternal prebiotics supplementation on child allergic disease outcomes. Eligible pregnant women have infants with a first-degree relative with a history of medically diagnosed allergic disease. Consented women are randomised to consume either prebiotics (galacto-oligosaccharides and fructo-oligosaccharides) or placebo (maltodextrin) powder daily from 18-20 weeks' gestation to six months' post-partum. The target sample size is 652 women. The primary outcome is infant medically diagnosed eczema; secondary outcomes include allergen sensitisation, food allergies and recurrent wheeze. Breast milk, stool and blood samples are collected at multiple timepoints for further analysis.
Asunto(s)
Dermatitis Atópica , Hipersensibilidad a los Alimentos , Niño , Dermatitis Atópica/tratamiento farmacológico , Dieta , Suplementos Dietéticos , Femenino , Hipersensibilidad a los Alimentos/tratamiento farmacológico , Humanos , Lactante , Oligosacáridos/uso terapéutico , Periodo Posparto , Prebióticos , Embarazo , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Consumption of a high-fat diet (HFD) not only increases the risk of metabolic syndrome but also initiates kidney injury. Lipid accumulation-induced systemic low-grade inflammation is an upstream mechanism of kidney injury associated with prediabetes. Chitosan oligosaccharide (COS) provides potent anti-obesity effects through several mechanisms including fecal lipid excretion. In this study, we investigated the effects of COS on the prevention of obesity-related complications and its ability to confer renoprotection in a prediabetic model. Rats fed on a HFD developed obesity, glucose intolerance and kidney dysfunction. COS intervention successfully ameliorated these conditions (p < 0.05) by attenuating intestinal lipid absorption and the renal inflammation-autophagy-apoptosis axis. A novel anti-inflammatory effect of COS had been demonstrated by the strengthening of intestinal barrier integrity via calcium-sensing receptor (p < 0.05). The use of COS as a supplement may be useful in reducing prediabetic complications especially renal injury and the risk of type 2 diabetes.
Asunto(s)
Quitosano , Diabetes Mellitus Tipo 2 , Estado Prediabético , Animales , Autofagia , Quitosano/metabolismo , Quitosano/farmacología , Quitosano/uso terapéutico , Diabetes Mellitus Tipo 2/metabolismo , Dieta Alta en Grasa , Inflamación/metabolismo , Riñón , Lípidos , Obesidad/metabolismo , Oligosacáridos/metabolismo , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Estado Prediabético/complicaciones , Estado Prediabético/tratamiento farmacológico , Estado Prediabético/metabolismo , RatasRESUMEN
Metabolic syndrome (MS) is a group of abnormalities in which obesity, insulin resistance (IR), oxidative stress, and dyslipidemia stand out. This pathology predisposes to the development of cardiovascular diseases and diabetes. The ingestion of linear fructooligosaccharides (FOS) such as inulin reduces conditions such as hyperinsulinemia, increased body fat, and triglyceridemia. When FOS are esterified with fatty acids, they present emulsifying and surfactant properties; however, there are no reports of their function at the biological level. The purpose of this investigation was to evaluate the effect of Agave tequilana Weber's FOS (AtW-FOS) and FOS esterified with lauric acid (FOS-LA) in MS markers in a rat model induced by a HFHC diet. Supplementation with AtW-FOS and FOS-LA decreased IR, improved glucose tolerance, reduced liver weight (19%), plasma triglycerides (24%), and blood pressure (16%) when compared with the untreated MS group. In conclusion, the ingestion of AtW-FOS and FOS-LA has beneficial effects in the prevention of MS alterations, showing a high potential for their application in functional foods.
Asunto(s)
Resistencia a la Insulina , Síndrome Metabólico , Tejido Adiposo/metabolismo , Animales , Dieta Alta en Grasa/efectos adversos , Ácidos Láuricos , Síndrome Metabólico/tratamiento farmacológico , Síndrome Metabólico/metabolismo , Oligosacáridos/uso terapéutico , Ratas , Ratas WistarRESUMEN
Prebiotics may promote immune homeostasis and reduce sub-clinical inflammation in humans. This study investigated the effect of prebiotic galactooligosaccharide (GOS) supplementation in colonic inflammation. Seventeen patients with active ulcerative colitis (UC) consumed 2.8 g/d GOS for 6 weeks. At baseline and 6 weeks, gene expression (microarray), fecal calprotectin (ELISA), microbiota (16S rRNA), short-chain fatty acids (SCFAs; gas-liquid chromatography), and clinical outcomes (simple clinical colitis activity index (SCCAI), gastrointestinal symptom rating scale (GSRS), and Bristol stool form scale (BSFS)) were measured. Following prebiotics, clinical scores (SCCAI), fecal calprotectin, SCFAs, and pH were unchanged. Five genes were upregulated and two downregulated. Normal stool proportion (BSFS) increased (49% vs. 70%, p = 0.024), and the incidence (46% vs. 23%, p = 0.016) and severity (0.7 vs. 0.5, p = 0.048) of loose stool (GSRS), along with urgency (SCCAI) scores (1.0 vs. 0.5, p = 0.011), were reduced. In patients with a baseline SCCAI ≤2, prebiotics increased the relative abundance of Bifidobacterium from 1.65% (1.97) to 3.99% (5.37) (p = 0.046) and Christensenellaceae from 0.13% (0.33) to 0.31% (0.76) (p = 0.043). Prebiotics did not lower clinical scores or inflammation but normalized stools. Bifidobacterium and Christensenellaceae proportions only increased in patients with less active diseases, indicating that the prebiotic effect may depend on disease activity. A controlled study is required to validate these observations.
Asunto(s)
Colitis Ulcerosa/sangre , Colitis Ulcerosa/genética , Suplementos Dietéticos , Microbioma Gastrointestinal/genética , Regulación de la Expresión Génica , Oligosacáridos/uso terapéutico , Prebióticos , Adulto , Colitis Ulcerosa/tratamiento farmacológico , Heces/microbiología , Humanos , Análisis de Componente Principal , Resultado del TratamientoRESUMEN
Breastmilk is known to be very important for infants because it provides nutrients and immunological compounds. Among these compounds, human milk oligosaccharides (HMOs) represent the third most important component of breastmilk after lipids and lactose. Several experiments demonstrated the beneficial effects of these components on the microbiota, the immune system and epithelial barriers, which are three major biological systems. Indeed, HMOs induce bacterial colonization in the intestinal tract, which is beneficial for health. The gut bacteria can act directly and indirectly on the immune system by stimulating innate immunity and controlling inflammatory reactions and by inducing an adaptive immune response and a tolerogenic environment. In parallel, HMOs directly strengthen the intestinal epithelial barrier, protecting the host against pathogens. Here, we review the molecular mechanisms of HMOs in these different compartments and highlight their potential use as new therapeutic agents, especially in allergy prevention.
Asunto(s)
Leche Humana/inmunología , Oligosacáridos/inmunología , Inmunidad Adaptativa , Animales , Bacterias/efectos de los fármacos , Bacterias/inmunología , Bacterias/metabolismo , Estudios Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Ácidos Grasos Volátiles/metabolismo , Microbioma Gastrointestinal , Humanos , Sistema Inmunológico , Inmunidad Innata , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/inmunología , Mucosa Intestinal/metabolismo , Mucosa Intestinal/microbiología , Microbiota , Oligosacáridos/química , Oligosacáridos/farmacología , Oligosacáridos/uso terapéutico , Permeabilidad , Relación Estructura-ActividadRESUMEN
Constipation is a frequent problem in children. We evaluated the effect of a mixture (polydextrose [PDX] and fructooligosaccharide [FOS]) in children with constipation. We performed a prospective interventional study with a mixture (PDX 4.17 g and FOS 0.45 g) in a daily dose of food supplement. The intervention lasted 45 days, with visits at 15, 30, and 45 days after administration. The sample comprised 105 patients, of whom 77 completed the intervention. A statistically significant reduction in the frequency of symptoms was observed at the end of the study. The frequency of children with fewer than three bowel movements per week dropped from 59.7% to 11.7%, and there was a decrease in the frequency of Bristol type 1 and 2 dry stools (68.8% to 7.8%), pain on defecation (79.2% to 10.4%), and fear of defecation (68.8% to 3.9%). The proportion of children with abdominal pain symptoms decreased from 84.2% to 2.6% at the end of the study. A relevant limitation of the present study was the lack of a control group treated with placebo. The administration of the PDX/FOS mixture was accompanied by a significant reduction in the frequency of constipation symptoms of the children evaluated. The tolerability was very good, and the rate of adverse effects was low.
Asunto(s)
Estreñimiento/dietoterapia , Suplementos Dietéticos , Glucanos/uso terapéutico , Oligosacáridos/uso terapéutico , Niño , Preescolar , Fibras de la Dieta/administración & dosificación , Fibras de la Dieta/uso terapéutico , Quimioterapia Combinada , Femenino , Glucanos/administración & dosificación , Humanos , Masculino , Oligosacáridos/administración & dosificaciónRESUMEN
Human milk (HM) is the gold standard for the nutrition of infants. An important component of HM is human milk oligosaccharides (hMOs), which play an important role in gut microbiota colonization and gut immune barrier establishment, and thereby contribute to the maturation of the immune system in early life. Guiding these processes is important as disturbances have life-long health effects and can lead to the development of allergic diseases. Unfortunately, not all infants can be exclusively fed with HM. These infants are routinely fed with infant formulas that contain hMO analogs and other non-digestible carbohydrates (NDCs) to mimic the effects of hMOs. Currently, the hMO analogs 2'-fucosyllactose (2'-FL), galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), and pectins are added to infant formulas; however, these NDCs cannot mimic all hMO functions and therefore new NDCs and NDC mixtures need to become available for specific groups of neonates like preterm and disease-prone neonates. In this review, we discuss human data on the beneficial effects of infant formula supplements such as the specific hMO analog 2'-FL and NDCs as well as their mechanism of effects like stimulation of microbiota development, maturation of different parts of the gut immune barrier and anti-pathogenic effects. Insights into the structure-specific mechanisms by which hMOs and NDCs exert their beneficial functions might contribute to the development of new tailored NDCs and NDC mixtures. We also describe the needs for new in vitro systems that can be used for research on hMOs and NDCs. The current data suggest that "tailored infant formulas" for infants of different ages and healthy statuses are needed to ensure a healthy development of the microbiota and the gut immune system of infants.
Asunto(s)
Suplementos Dietéticos , Fórmulas Infantiles , Oligosacáridos/uso terapéutico , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Inmunidad Mucosa/efectos de los fármacos , Fenómenos Fisiológicos Nutricionales del Lactante , Recién Nacido , Oligosacáridos/administración & dosificación , Oligosacáridos/farmacologíaRESUMEN
To explore the protective effect of Fructooligosaccharides (FOS) against Enterotoxigenic Escherichia coli (ETEC)-induced inflammation and intestinal injury, twenty-four weaned pigs were randomly assigned into three groups: (1) non-challenge (CON, fed with basal diet), (2) ETEC-challenge (ECON, fed with basal diet), and (3) ETEC challenge + FOS treatment (EFOS, fed with basal diet plus 2.5 g kg-1 FOS). On day 19, the CON group was orally infused with sterilized culture while pigs in the ECON group and EFOS group were orally infused with ETEC (2.5 × 1011 colony-forming units). After 3 days, pigs were slaughtered for sample collection. We showed that ETEC challenge significantly reduced average daily gain (ADG); however, FOS improved the ADG (P < 0.05), apparent digestibility of crude protein (CP), gross energy (GE), and ash and reduced the diarrhea incidence (P < 0.05). FOS reduced plasma concentrations of IL-1ß and TNF-α and down-regulated (P < 0.05) the mRNA expression of IL-6 and TNF-α in the jejunum and ileum as well as IL-1ß and TNF-α in the duodenum. The concentrations of plasma immunoglobulin A (IgA), immunoglobulin M (IgM) and secreted IgA (SIgA) in the jejunum (P < 0.05) were elevated. Interestingly, FOS elevated the villus height in the duodenum, and elevated the ratio of villus height to crypt depth in the duodenum and ileum in the EFOS group pigs (P < 0.05). Moreover, FOS increased lactase activity in the duodenum and ileum (P < 0.05). The activities of sucrase and alkaline phosphatase (AKP) were higher in the EFOS group than in the ECON group (P < 0.05). Importantly, FOS up-regulated the expressions of critical genes in intestinal epithelium function such as zonula occludens-1 (ZO-1), L-type amino acid transporter-1 (LAT1), and cationic amino acid transporter-1 (CAT1) in the duodenum and the expressions of ZO-1 and glucose transporter-2 (GLUT2) in the jejunum (P < 0.05). FOS also up-regulated the expressions of occludin, fatty acid transporter-4 (FATP4), sodium glucose transport protein 1 (SGLT1), and GLUT2 in the ileum (P < 0.05). FOS significantly increased the concentrations of acetic acid, propionic acid and butyric acid in the cecal digesta. Additionally, FOS reduced the populations of Escherichia coli, but elevated the populations of Bacillus and Bifidobacterium in the caecal digesta (P < 0.05). These results suggested that FOS could improve the growth performance and intestinal health in weaned pigs upon ETEC challenge, which was associated with suppressed inflammatory responses and improved intestinal epithelium functions and microbiota.
Asunto(s)
Escherichia coli Enterotoxigénica/patogenicidad , Infecciones por Escherichia coli/veterinaria , Oligosacáridos/uso terapéutico , Probióticos/uso terapéutico , Enfermedades de los Porcinos/prevención & control , Administración Oral , Animales , Animales Recién Nacidos , Suplementos Dietéticos , Infecciones por Escherichia coli/microbiología , Infecciones por Escherichia coli/prevención & control , Mucosa Intestinal/efectos de los fármacos , Oligosacáridos/administración & dosificación , Oligosacáridos/farmacología , Probióticos/administración & dosificación , Probióticos/farmacología , Porcinos , Enfermedades de los Porcinos/microbiología , Resultado del TratamientoRESUMEN
We investigated the therapeutic potential and mechanism of chitosan oligosaccharides (COS) for experimental autoimmune uveoretinitis (EAU) in mice. EAU was induced in C57/BL6 mice by injection of human interphotoreceptor retinoid-binding protein (IRBP) peptides. At the same time, a high or low dose (20 or 10 mg/kg) of COS or phosphate-buffered saline (PBS) was given to mice daily after EAU induction. We found that mouse EAU is ameliorated by the high-dose COS treatment when compared with PBS treatment. In the retinas of high-dose COS-treated mice, the nuclear translocation of NF-κB subunit (p65) was suppressed, and the expression of several key EAU inflammatory mediators, IFN-γ, TNF-α, IL-1α, IL-4, IL-5, IL-6, IL-10, IL-17 and MCP-1 was lowered. These results suggest that COS may be a potential treatment for posterior uveitis.
Asunto(s)
Quitosano/farmacología , FN-kappa B/metabolismo , Retinitis/tratamiento farmacológico , Animales , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/inmunología , Quitosano/metabolismo , Modelos Animales de Enfermedad , Proteínas del Ojo/efectos adversos , Proteínas del Ojo/metabolismo , Femenino , Inflamación/metabolismo , Interleucina-17/inmunología , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos C57BL , Oligosacáridos/uso terapéutico , Retina/metabolismo , Proteínas de Unión al Retinol/efectos adversos , Proteínas de Unión al Retinol/metabolismo , Factor de Necrosis Tumoral alfa/inmunología , Uveítis/tratamiento farmacológico , Uveítis/metabolismoRESUMEN
PURPOSE: To investigate the protective effect of Oligosaccharides composition of Descurainiae sophia on doxorubicin-induced heart failure in rats, and to study its mechanism. METHOD: A rat model of heart failure was established in 180-220â¯g male Sprague-Dawley rats by low-dose intraperitoneal injection of doxorubicin for 6 weeks. Four weeks after continuous administration, echocardiography was used to detect left ventricular end diastolic diameter (LVEDD) and end systolic diameter (LVESD) in each group, and left ventricular short axis shortening rate (LVFS) and ejection fraction (LVEF) were calculated. ELISA method was used to detecte the levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), troponin I (cTnI), creatine kinase (CK), angiotensin II (Ang II), aldosterone (ALD), arginine pressurization AVP, Renin, Endothelin (ET-1), Nitric Oxide (NO), AQP2 in urine. 6â¯h cumulative urine output was measured by metabolic cage method after administration for 3 weeks. The urine osmotic pressure was measured by freezing point method. The expression of AQP2 protein in kidney was detected by Western blot method. The changes of myocardial morphology were observed. RESULTS: Compared with the normal control group, the heart rate of the model group was significantly increased (Pâ¯<â¯0.01). LVESD and LVEDD were significantly increased (Pâ¯<â¯0.01), LVEF and LVFS were significantly decreased (Pâ¯<â¯0.01). The levels of CK, cTnI, NO, ET-1, BNP, ANP, ALD, AngII, Renin, AQP2, AVP and osmotic pressure were significantly increased (Pâ¯<â¯0.01). Urine output was significantly decreased (Pâ¯<â¯0.01). The heart HE showed obvious lesions. Compared with the model group, the Oligosaccharides composition of Descurainiae sophia significantly reduced the heart rate (Pâ¯<â¯0.05), decreased LVESD and LVEDD (Pâ¯<â¯0.01 or Pâ¯<â¯0.05), and increased LVFS and LVEF values (Pâ¯<â¯0.01). Oligosaccharides composition of Descurainiae sophia could significantly improve pathological damage of the heart, decrease the levels of cTnI, BNP, AngII, ALD, Renin, AVP in the serum, osmotic pressure and AQP2in the urine (Pâ¯<â¯0.01 or Pâ¯<â¯0.05), down-regulate the expression of AQP2 protein in the renal(Pâ¯<â¯0.01), increase urine volume (Pâ¯<â¯0.05). CONCLUSION: Oligosaccharides composition of Descurainiae sophia can significantly improve cardiac function and the disorder of water metabolism in rats with heart failure. Oligosaccharides composition of Descurainiae sophia exerts anti- heart failure through the RAAS system and the arginine vasopressin system.
Asunto(s)
Brassicaceae/química , Insuficiencia Cardíaca/tratamiento farmacológico , Ventrículos Cardíacos/efectos de los fármacos , Oligosacáridos/uso terapéutico , Agua/metabolismo , Animales , Acuaporina 2/orina , Modelos Animales de Enfermedad , Insuficiencia Cardíaca/metabolismo , Insuficiencia Cardíaca/patología , Pruebas de Función Cardíaca , Frecuencia Cardíaca/efectos de los fármacos , Ventrículos Cardíacos/metabolismo , Ventrículos Cardíacos/patología , Ventrículos Cardíacos/fisiopatología , Masculino , Oligosacáridos/aislamiento & purificación , Ratas Sprague-Dawley , Semillas/químicaRESUMEN
INTRODUCTION: Cow's milk allergy (CMA) is one of the most common food allergies especially early in life. A mixture of nondigestible short-chain galacto-oligosaccharides, long-chain fructo-oligosaccharides, and pectin-derived acidic-oligosaccharides (GFA) may reduce allergy development and allergic symptoms in murine CMA. Recently, vitamin D (VitD) has been suggested to have beneficial effects in reducing allergy as well. OBJECTIVE: In this study, the immune modulatory effect on allergy prevention using the combination of GFA and VitD was investigated. METHODS: Female C3H/HeOuJ mice were fed a control or GFA-containing diet with depleted, standard (1,000 IU/kg), or supplemented (5,000 IU/kg) VitD content for 2 weeks before and during whey sensitization (n = 10-15). Mice were sensitized 5 times intragastrically with PBS as a control, whey as cow's milk allergen, and/or cholera toxin as adjuvant on a weekly interval. One week after the last sensitization, mice were intradermally challenged in both ear pinnae and orally with whey, subsequently the acute allergic skin response and shock symptoms were measured. After 18 h, terminal blood samples, mesenteric lymph nodes, and spleens were collected. Whey-specific immunoglobulin (Ig) E and IgG1 levels were measured by means of ELISA. T cell subsets and dendritic cells (DCs) were studied using flow cytometry. RESULTS: Additional VitD supplementation did not lower the allergic symptoms compared to the standard VitD diet. CMA mice fed the GFA diet supplemented with VitD (GFA VitD+) significantly decreased the acute allergic skin response of whey sensitized mice when compared to the CMA mice fed VitD (VitD+) group (p < 0.05). The effect of GFA was not improved by extra VitD supplementation even though the CMA mice fed the GFA VitD+ diet had a significantly increased percentage of CD103+ DCs compared to the VitD+ group (p < 0.05). The VitD-deprived mice showed a high percentage of severe shock and many reached the humane endpoint; therefore, these groups were not further analyzed. CONCLUSIONS: High-dose VitD supplementation in mice does not protect against CMA development in the presence or absence of GFA.
Asunto(s)
Células Dendríticas/inmunología , Hipersensibilidad a la Leche/dietoterapia , Piel/patología , Linfocitos T Reguladores/inmunología , Vitamina D/uso terapéutico , Alérgenos/inmunología , Animales , Bovinos , Dieta , Suplementos Dietéticos , Modelos Animales de Enfermedad , Femenino , Humanos , Inmunoglobulina E/metabolismo , Ratones , Ratones Endogámicos C3H , Leche/inmunología , Oligosacáridos/uso terapéuticoRESUMEN
Codonopsis pilosula is a traditional Chinese medicine and food supplement that is widely used in China. This study aimed to investigate the antifatigue and antihypoxia activities of different extracts and fractions from C. pilosula, including ethanol extract (ETH), water extract (WAT), polysaccharides (POL), inulin (INU) and oligosaccharides (OLI). Different extracts and fractions were orally administered to mice at the doses of 0.25, 0.5 and 1.0 g kg-1 once a day for 21 days. Antifatigue activity was assessed through the weight-loaded swimming test on the 21st day, and antihypoxia activity was evaluated through the normobarie hypoxia test on the following day. Finally, biochemical parameters, such as liver glycogen (LG), muscle glycogen (MG), blood urea nitrogen (BUN), lactic dehydrogenase (LDH), malondialdehyde (MDA), and glutathione (GSH) levels, were determined. The results showed that, compared with the control treatment, only POL treatment significantly prolonged the swimming time of the mice. POL groups had the strongest hypoxia tolerance, followed by the OLI and WAT groups. The levels of LG and MG were significantly increased by treatment with POL at the doses of 0.5 and 1.0 g kg-1, whereas BUN and LDH levels in POL groups were significantly lower than those in the control group. MDA under POL and OLI treatment was significantly lower than that under the control treatment. In addition, treatments with POL and OLI, except for treatment with a low dose of OLI, significantly increased GSH levels. In conclusion, POL could efficiently enhance antifatigue and antihypoxia abilities by increasing energy resources, decreasing detrimental metabolite accumulation, and enhancing antioxidant activity. OLI could improve antihypoxia activity by preventing lipid peroxidation and enhancing antioxidant activity.